Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
CSTL
#2185
Castle Biosciences, Inc. Common Stock
29.570
0
-3.05%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-3.05%
Aylık değişim
-30.88%
6 aylık değişim
+20.13%
Yıllık değişim
+20.13%
Önceki kapanış
30.500
0
Open
29.570
0
Bid
Ask
Low
29.570
0
High
29.570
0
Hacim
98
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
CSTL
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
28.01 M
28.51 M
28.87 M
29.01 M
29.19 M
29.73 M
—
Valuation ratios
Enterprise value
703.77 M
640.2 M
488.32 M
510.15 M
579.03 M
1.04 B
2.62 B
Price to earnings ratio
129.64
42.98
-105.37
-58.34
-50.6
-46.87
-261.18
Price to sales ratio
2.56
2.35
1.66
1.7
1.91
—
—
Price to cash flow ratio
39.27
12.02
9.04
9.47
10.68
17.52
46.71
Price to book ratio
0.48
1.71
0.33
0.33
0.36
2.39
3.41
Enterprise value to EBITDA ratio
122.35
26.04
22.28
40.38
561.62
—
—
Profitability ratios
Return on assets %
0
0.01
0.05
0.01
0
-0.01
0.05
Return on equity %
0.01
0.01
0.06
0.01
0
-0.01
0.06
Return on invested capital %
5.67
-7.65
66.2
3.41
13.84
7.16
90.61
Gross margin %
81.8
81.25
81.38
79.55
77.48
78.95
317.36
Operating margin %
5.92
-7.99
31.74
4.93
8.19
4.4
49.26
EBITDA margin %
10.02
3.54
2.12
-1.02
-3.63
-37.48
-40.01
Net margin %
2.65
5.24
29.38
5.25
0.6
-7.72
27.51
Liquidity ratios
Quick ratio
7.64
7.13
9.19
6.69
6.31
5.11
27.29
Current ratio
7.78
7.29
9.37
6.85
6.47
5.26
27.95
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.17
0.17
0.17
0.16
0.15
0.15
0.64
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.02
0.02
0.02
0.01
0.02
0.02
0.07
Long term debt to total equity ratio
0.02
0.02
0.02
0.02
0.02
0.02
0.08
Per share metrics
Operating cash flow per share
0.79
0.83
0.21
0.3
0.78
0.93
2.21
EBIT per share
0.17
-0.09
-0.98
-0.15
-0.23
-1.26
-2.61
EBITDA per share
0.29
0.1
0.07
-0.03
-0.1
-1.13
-1.19
Total debt per share
—
—
—
—
—
—
—
Cash per share
9.52
9.9
16.1
15.71
16.84
16.64
65.28
Net current asset value per share
11.73
12.31
12.21
11.8
12.3
12.46
48.77
Tangible book value per share
11.24
11.95
12.67
11.89
12.56
12.81
49.93
Working capital per share
10.22
10.62
10.91
10.08
10.4
10.09
41.47
Book value per share
15
15.58
15.39
15.41
16.06
16.24
63.11
Haberler
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates
Castle Biosciences 4Ç 2025: Test hacimleri %42 arttı, AD pazarına girdi
Castle Biosciences Q4 2025 slides: test volumes surge 42%, enters AD market
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up